These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2164039)

  • 1. Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers.
    Komatsu T; Yamauchi K; Furukawa T; Obata H
    J Clin Immunol; 1990 May; 10(3):167-74. PubMed ID: 2164039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
    Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
    Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
    Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction and clinical utilization of lymphokine-activated killer cells in patients with gastrointestinal tract cancers.
    Tsugita M; Yamauchi K; Komatsu T; Suzuki H; Hanyu F
    J Gastroenterol Hepatol; 1990; 5(2):110-5. PubMed ID: 2103390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma.
    Yamamoto M; Iizuka H; Fujii H; Matsuda M; Miura K
    Acta Oncol; 1993; 32(1):43-51. PubMed ID: 8385472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative chemoimmunotherapy for the treatment of liver cancer.
    Uchino J; Une Y; Kawata A; Wakisaka Y; Hosokawa M
    Semin Surg Oncol; 1993; 9(4):332-6. PubMed ID: 8210915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experiences of LAK therapy in patients with hepatocellular carcinoma].
    Zeki K; Sakamoto H; Okuno F; Sujita K; Eto S
    J UOEH; 1989 Sep; 11(3):341-5. PubMed ID: 2554458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.
    Ishikawa T; Imawari M; Moriyama T; Ohnishi S; Matsuhashi N; Suzuki G; Takaku F
    J Cancer Res Clin Oncol; 1988; 114(3):283-90. PubMed ID: 2838488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.
    Okuno K; Takagi H; Nakamura T; Nakamura Y; Iwasa Z; Yasutomi M
    Cancer; 1986 Sep; 58(5):1001-6. PubMed ID: 2425926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of depressed lymphokine activated killer cell activity in patients with hepatocellular carcinoma.
    Saibara T; Onishi S; Matsuura Y; Fujikawa M; Sakaeda H; Matsunaga Y; Yamamoto Y
    Biotherapy; 1990; 2(1):1-12. PubMed ID: 2169282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.
    Onishi S; Saibara T; Fujikawa M; Sakaeda H; Matsuura Y; Matsunaga Y; Yamamoto Y
    Hepatology; 1989 Sep; 10(3):349-53. PubMed ID: 2474481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2.
    Ichida T; Higuchi K; Arakawa K; Ohta H; Sugiyama K; Miyagiwa M; Nohzawa A; Satoh T; Sasaki H; Ichida F
    Cancer Chemother Pharmacol; 1989; 23 Suppl():S45-8. PubMed ID: 2538266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study.
    Ferlazzo G; Scisca C; Iemmo R; Cavaliere R; Quartarone G; Adamo V; Frazzetto G; Costa G; Melioli G
    J Immunother; 1997 Mar; 20(2):158-63. PubMed ID: 9087388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.